Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/KCT0000355
KCT0000355Recruiting未知

Prevention of Cardiovascular events in ischemic stroke patients with high risk of cerebral hemorrhage: PICASSO study

Asan Medical Center0 sites1,600 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Recruiting
Enrollment
1,600
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional Study

Eligibility Criteria

Ages
40(Year) to 0No Limit (—)
Sex
All

Inclusion Criteria

  • •patinets having high-risk of cerebral hemorrage proved by past history of cerebral hemorrhage or multiple microbleeds on MRI among acute stroke patients who were admitted in 4 hostpitals

Exclusion Criteria

  • •acute stroke patients with cardioembolic source or
  • •patients within 6 months of life expectancy

Investigators

Similar Trials

Completed
Not Applicable
Improving the prevention of vascular events after stroke or transient ischemic attackStroke
ISRCTN63816609Royal Devon and Exeter Foundation Trust (UK)30
Active, not recruiting
Phase 1
Can the heart drug enalapril prevent heart damage in patients with newly diagnosed breast cancer and lymphoma receiving chemotherapy?Prevention of cardiotoxicityMedDRA version: 20.0Level: PTClassification code 10048610Term: CardiotoxicitySystem Organ Class: 10007541 - Cardiac disorders
EUCTR2017-001094-16-GBSouth Tees NHS Foundation Trust170
Completed
Not Applicable
Secondary Prevention of Adverse Cardiovascular Events in Cases with Anomalous Origins of Coronary Arteries: Clinical Features, Management, and Long-Term OutcomeAnomalous Origin of the Coronary Artery
JPRN-UMIN000030629ihon University60
Active, not recruiting
Not Applicable
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190
EUCTR2005-003700-10-BEInstitut de Recherches Internationales Servier18,000
Active, not recruiting
Not Applicable
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORM
EUCTR2005-003700-10-LTInstitut de Recherches Internationales Servier18,000